- Publication status:
- Publisher copy:
- Copyright date:
Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.
If you are the owner of this record, you can report an update to it here: Report update to this record